

CV

Dr. Torsten Woehr

Dr. Torsten Woehr, brings more than 25 years of experience in the international CDMO, biotechnology and pharmaceutical industries. He combines strong commercial leadership with deep operational understanding and has a proven track record in scaling businesses, building strategic partnerships, driving sustainable growth and aligning commercial priorities with operational capabilities.

Before joining Rentschler Biopharma in August 2026, Dr. Woehr served as Chief Commercial Officer of Bachem Group, a publicly listed CDMO focused on peptide- and oligonucleotide-based active pharmaceutical ingredients. As a member of Bachem's Executive Team, he led global commercial activities, worked closely with the Board on strategic initiatives and contributed to significant topline growth, supported by optimized use of production assets and strong profitability.

He also shaped the commercial strategy behind major capacity expansions, including Bachem's new production facility in Bubendorf, and helped secure long-term customer commitments with substantial annual order volumes. In this role, he led a commercial organization of more than 100 employees across Marketing, Business Development, Sales, CDMO Project Management, Strategic Alliances and Contract Negotiation.

Previously at Bachem, he held senior leadership roles including Vice President and Head of Oligonucleotides, where he launched the company's custom manufacturing offering for nucleic-acid-based APIs, built the core team, established manufacturing infrastructure and secured strategic partnerships. Earlier, as Sales Director Commercial APIs, he led sales for Bachem's commercial API portfolio and secured important business for commercial peptide APIs.

His international experience includes more than a decade in the United States, where he held senior commercial and business development positions in the Boston area. At Abcam, he established and led a Commercial Marketing function for markets in drug discovery, development and diagnostics. At Genzyme Pharmaceuticals and CordenPharma, he built the "Bio-organics platform" for API and excipient manufacturing, which later became a key growth driver for Genzyme/CordenPharma.

Dr. Woehr began his industry career in regulatory affairs at Johnson & Johnson, supporting market-approved recombinant biologics.

He holds a doctorate in bioorganic chemistry from the University of Lausanne / Swiss Federal Institute of Technology, Lausanne, and an MBA Industrial Engineering and General Management from ETH Zürich, Switzerland.